# Chengdu Easton Biopharmaceuticals Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chengdu-easton-biopharmaceuticals-co

- Industry: Pharmaceuticals
- Headquarters: Chengdu, China
- Website: www.eastonpharma.cn
- Latest round: Series A (Jul 7, 2015)
- Investors on record: 2

## About

Established in 2009 and based in Chengdu, China, Chengdu Easton Biopharmaceuticals Co., Ltd operates as a pharmaceutical company dedicated to providing chemical drugs. It has branch-offices in Shanghai and Xizang. The company has 115 patents, including 106 invention patents. It also acquired certifications such as US FDA and EU EMA certification. Easton Biopharmaceuticals has 426 R&D employees. In May 2016, Easton Biopharmaceuticals was listed on the New Third Board. In December 2016, the company raised CNY 70 million in venture funding. In September 2020. Easton Biopharmaceuticals was listed on the Shanghai Stock Exchange Sci-Tech Innovation Board. 

The company mainly provides preparation products and active pharmaceutical ingredients. The main products include moxifloxacin hydrochloride, fluoxetine maleate, sodium ibandronate injection, and vecuronium bromide for injection. The preparation products cover the fields of cardiovascular and cerebrovascular diseases, oncology, endocrinology, central nervous system, and other fields. Easton Biopharmaceuticals has industrialized nearly 30 chemical active pharmaceutical products, and more than 10 chemical active pharmaceutical products have been exported to the international market.

In 2022, the company's revenue was CNY 1.17 billion, and its net income was CNY 246.52 million.

## Funding rounds

- Series A, Jul 7, 2015 — LYFE Capital, CreditEase Fintech Investment Fund

## Investors

- LYFE Capital — Series A
- CreditEase Fintech Investment Fund (https://capitalatlas.ai/funds/creditease-fintech-investment-fund) — Series A